Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 4/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8337750 | 1.00 | CA2 (0.42) | CA2CA4TDP1SMN1; SMN2MME | |
| SCHEMBL13654785 | 0.88 | CA2 (0.51) | CA2CA4SMN1; SMN2MMEFNTA | |
| SCHEMBL21954042 | 0.82 | GABRR1 (0.33) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL13020988 | 0.82 | ALOX15 (0.34) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL2918805 | 0.82 | ECE1 (0.42) | CA2FOLH1MAPT | |
| SCHEMBL8028150 | 0.82 | ECE1 (0.42) | CA2FOLH1MAPT | |
| SCHEMBL28337307 | 0.82 | KDM4E (0.38) | TDP1SMN1; SMN2MMEFNTAFNTB | |
| SCHEMBL14989156 | 0.81 | EPHX2 (0.37) | CA2CA4MAPT | |
| SCHEMBL9021257 | 0.80 | SLC22A6 (0.32) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL5088899 | 0.79 | CA2 (0.41) | CA2CA4TDP1SMN1; SMN2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120119253-A | High-stability titanium etching solution and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2025-06-10 | — | — | CN | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| CN-117589713-A | Method for selectively regulating and enhancing binding capacity of different subtype 5-hydroxytryptamine receptors and classical hallucinogens and application thereof | 中国科学院长春应用化学研究所 | 2024-02-23 | — | — | CN | claimed |
| CN-109010830-A | Application of the blood platelet related inhibitors in preparation treatment decrease of platelet disease drug | 苏州大学 | 2018-12-18 | — | — | CN | claimed |
| CN-1889974-A | Oligopeptides as coating material for medical products | HEMOTEQ GMBH (DE) | 2007-01-03 | — | — | CN | claimed |
| US-20040137559-A1 | Process for producing N-formylamino acid and use thereof | AJINOMOTO CO., INC. (JP) | 2004-07-15 | — | — | US | claimed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250185669-A1 | ANTI-VIRAL PAINTS AND COATINGS AND ARTICLES COMPRISING SAME | Reactive Surfaces Ltd., LLP (US) | 2025-06-12 | — | — | US | disclosed |
| CN-120119253-A | High-stability titanium etching solution and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025054048-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-12232498-B2 | Anti-viral paints and coatings and articles comprising same | Reactive Surfaces Ltd., LLP (US) | 2025-02-25 | — | — | US | disclosed |
| CN-85101227-A | The preparation method of novel alpha-chlorinated carbonates and application | — | 1987-01-24 | — | — | CN | disclosed |
| EP-0093128-B1 | PROCESS FOR PREPARING OF METHYL ESTER OF ALPHA-ASPARTYL PHENYL ALANINE | LABORATOIRES FOURNIER S.A. (FR) | 1985-08-21 | — | — | EP | disclosed |
| EP-0055612-B1 | RECOVERY OF L-PHENYLALANINE AND L-ASPARTIC ACID DURING PREPARATION OF ALPHA-L-ASPARTYL-L-PHENYLALANINE METHYL ESTER | MONSANTO COMPANY (US) | 1984-08-08 | — | — | EP | disclosed |
| EP-0093128-A1 | PROCESS FOR PREPARING OF METHYL ESTER OF ALPHA-ASPARTYL PHENYL ALANINE. | FOURNIER LAB SA (FR) | 1983-11-09 | — | — | EP | disclosed |
| WO-1983001619-A1 | METHOD FOR THE PREPARATION OF METHYL ESTER OF 'alpha'-ASPARTYL PHENYLALANINE | GOURBAULT, MAURICE, JEAN | 1983-05-11 | — | — | WO | disclosed |
| US-4348317-A | Recovery of L-phenylalanine and L-aspartic acid during preparation of α-L-aspartyl-L-phenylalanine methyl ester | MONSANTO COMPANY (US) | 1982-09-07 | — | — | US | disclosed |
| EP-0055612-A1 | Recovery of L-phenylalanine and L-aspartic acid during preparation of alpha-L-aspartyl-L-phenylalanine methyl ester | MONSANTO COMPANY (US) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | CA2 3043/4885CA4 2768/4885TDP1 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.